PCSK9 inhibitors, ezetimibe, and bempedoic acid are the three main non-statin lipid-lowering drugs: PCSK9 inhibitors reduce LDL particle clearance; ezetimibe blocks cholesterol reabsorption in the gut via the liver; and bempedoic acid is a liver-specific cholesterol synthesis inhibitor (unlike statins which act globally), with typical out-of-pocket costs of ~$500/month for PCSK9 inhibitors and bempedoic acid.
factualpending
Speaker
Peter AttiaEvidence Quote
“[21:53] 'PCSK9 inhibitors uh and then ezetimibe and bempedoic acid.'”
Source
The longevity treatment no one’s talking about: Peter Attia, M.D. | mbg Podcast— the mindbodygreen podcastCreated: 8/12/2026, 6:09:02 PM
Your notes
Loading notes...